Metabolic and glutathione redox markers associated with brain-derived neurotrophic factor in depressed african men and women: Evidence for counterregulation?

Neuropsychobiology

Volumn 67, Issue 1, 2013, Pages 33-40

  Harvey, Brian H ^a   Hamer, Mark ^a,c   Louw, Roan ^b   Van Der Westhuizen, Francois H ^b   Malan, Leoné ^a  

^a NORTH WEST UNIVERSITY   (South Africa)

^b Centre for Human Metabonomics   (Germany)

^c UNIVERSITY COLLEGE LONDON   (United Kingdom)

Author keywords

Black Africans; Brain derived neurotrophic factor; Counterregulation; Gender differences; Glutathione redox status; Major depression; Metabolic stress

Indexed keywords

BRAIN DERIVED NEUROTROPHIC FACTOR; GLUTATHIONE;

ADULT; AFRICA; ARTICLE; CONTROLLED STUDY; CORRELATIONAL STUDY; DEPRESSION; FEMALE; GLUTATHIONE METABOLISM; HUMAN; MAJOR CLINICAL STUDY; MALE; OXIDATION REDUCTION REACTION; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; WAIST CIRCUMFERENCE;

ADULT; AFRICAN CONTINENTAL ANCESTRY GROUP; BASAL METABOLISM; BIOLOGICAL MARKERS; BRAIN-DERIVED NEUROTROPHIC FACTOR; CASE-CONTROL STUDIES; DEPRESSIVE DISORDER, MAJOR; FEMALE; GLUTATHIONE; HUMANS; MALE; MIDDLE AGED; OXIDATION-REDUCTION; PSYCHIATRIC STATUS RATING SCALES; RISK FACTORS; SEX CHARACTERISTICS; SOUTH AFRICA; WAIST CIRCUMFERENCE;

EID: 84870378579     PISSN: 0302282X     EISSN: 14230224     Source Type: Journal    
DOI: 10.1159/000343501     Document Type: Article

References (59)

1. Kessler RC, Berglund P, Demler O, Jin R, Merikangas KR, Walters EE: Lifetime prevalence and age-of-onset distributions of DSM-IV disorders in the National Comor-bidity Survey Replication. Arch Gen Psychiatry 2005; 62: 593-602.
2. Kessler RC, Chiu WT, Demler O, Walters EE: Prevalence, severity, and comorbidity of twelve-month DSM-IV disorders in the National Comorbidity Survey Replication (NCS-R). Arch Gen Psychiatry 2005; 62: 617-627.
3. Marcus SM, Young EA, Kerber KB, Kornstein S, Farabaugh AH, Mitchell J, et al: Gender differences in depression: findings from the STAR*D study. J Affect Disord 2005; 87: 141-150.
4. Möller-Leimkühler AM: Higher comorbidi-ty of depression and cardiovascular disease in women: a biopsychosocial perspective. World J Biol Psychiatry 2010; 11: 922-933.
5. Lazarus RS: Coping theory and research: past, present, and future. Psychosom Med 1993; 55: 234-247.
6. Koolhaas JM, De Boer SF: Coping styles and aggression: a biobehavioral approach; in Vingerhoets A, Nylicek I, Denollet J (eds): Emotion Regulation: Conceptual and Clinical Issues. Berlin, Springer, 2008, pp 12-20.
7. Malan L, Malan NT, Wissing MP, Seedat YK: Coping with urbanization: a cardiometabol-ic risk? The THUSA study. Biol Psychol 2008; 79: 323-328.
8. Appels A: Mental precursors of myocardial infarction. Br J Psychiatry 1990; 56: 465-471.
9. Korner PI: Essential Hypertension and Its Causes: Neural and Non-Neural Mechanisms. New York, Oxford University Press, 2007, pp 347-358.
10. Hamer M, Malan L: Psychophysiological risk markers of cardiovascular disease. Neurosci Biobehav Rev 2010; 35: 76-83.
11. McEwen BS: Stress, adaptation, and disease. Allostasis and allostatic load. Ann NY Acad Sci 1998; 840: 33-44.
12. McEwen BS: Physiology and neurobiology of stress and adaptation: central role of the brain. Physiol Rev 2007; 87: 873-904.
13. Okamura F, Tashiro A, Utumi A, Imai T, Su-chi T, Tamura D, et al: Insulin resistance in patients with depression and its changes during the clinical course of depression: minimal model analysis. Metabolism 2000; 49: 1255-1260.
14. Dager SR, Friedman SD, Parow A, et al: Brain metabolic alterations in medication-free patients with bipolar disorder. Arch Gen Psychiatry 2004; 61: 450-458.
15. Regenold WT, Phatak P, Kling MA, Hauser P: Post-mortem evidence from human brain tissue of disturbed glucose metabolism in mood and psychotic disorders. Mol Psychiatry 2004; 9: 731-733.
16. Regenold WT, Hisley KC, Obuchowski A, Lefkowitz DM, Marano C, Hauser P: Relationship of white matter hyperintensities to cerebrospinal fluid glucose polyol pathway metabolites-a pilot study in treatment-resistant affective disorder patients. J Affect Disord 2005; 85: 341-350.
17. Kruse J, Petrak F, Herpertz S, Albus C, Lange K, Kulzer B: Diabetes and depression-a life-endangering interaction (in German). Z Psy-chosom Med Psychother 2006; 52: 289-309.
18. Hamer M, Batty GD, Kivimaki M: Haemoglobin A1c, fasting glucose and future risk of elevated depressive symptoms over 2 years of follow-up in the English Longitudinal Study of Ageing. Psychol Med 2011; 41: 1889-1896.
19. Harvey BH: Is major depressive disorder a metabolic encephalopathy? Hum Psycho-pharmacol 2008; 23: 371-384.
20. Maes M, Yirmyia R, Noraberg J, Brene S, Hibbeln J, Perini G, et al: The inflammatory and neurodegenerative hypothesis of depression: leads for future research and new drug developments in depression. Metab Brain Dis 2009; 24: 27-53.
21. Dantzer R, O'Connor JC, Lawson MA, Kel-ley KW: Inflammation-associated depression: from serotonin to kynurenine. Psycho-neuroendocrinology 2011; 36: 426-436.
22. Greco CM, Kao AH, Sattar A, Danchenko N, Maksimowicz-McKinnon KM, Edmundo-wicz D, et al: Association between depression and coronary artery calcification in women with systemic lupus erythematosus. Rheumatology 2009; 48: 576-581.
23. Joynt KE, Whellan DJ, O'Connor CM: Depression and cardiovascular disease: mechanisms of interaction. Biol Psychiatry 2003; 54: 248-261.
24. Shively CA, Musselman DL, Willard SL: Stress, depression, and coronary artery disease: modeling comorbidity in female primates. Neurosci Biobehav Rev 2009; 33: 133-144.
25. Gardner A, Boles RG: Beyond the serotonin hypothesis: mitochondria, inflammation and neurodegeneration in major depression and affective spectrum disorders. Prog Neu-ropsychopharmacol Biol Psychiatry 2011; 35: 730-743.
26. Ng F, Berk M, Dean O, Bush AI: Oxidative stress i n psychiat ric disorders: evidence base and therapeutic implications. Int J Neuro-psychopharmacol 2008; 11: 851-876.
27. Bains JS, Shaw CA: Neurodegenerative disorders in humans: the role of glutathione in oxidative stress-mediated neuronal death. Brain Res Rev 1997; 25: 335-358.
28. Johnson F, Giulivi C: Superoxide dismutases and their impact upon human health. Mol Aspects Med 2005; 26: 340-352.
29. Garcia-Cazorla A, Duarte S, Serrano M, Nascimento A, Ormazabal A, Carrilho I, et al: Mitochondrial diseases mimicking neurotransmitter defects. Mitochondrion 2008; 8: 273-278.
30. Sen S, Duman R, Sanacora G: Serum brain-derived neurotrophic factor, depression, and antidepressant medications: meta-analyses and implications. Biol Psychiatry 2008; 64: 527-532.
31. Dwivedi Y: Brain-derived neurotrophic factor: role in depression and suicide. Neuro-psychiatr Dis Treat 2009; 5: 433-449.
32. Martinez JM, Garakani A, Yehuda R, Gorman JM: Proinflammatory and 'resiliency' proteins in the CSF of patients with major depression. Depress Anxiety 2012; 29: 32-38.
33. Pan W, Banks WA, Fasold MB, Bluth J, Kastin AJ: Transport of brain-derived neuro-trophic factor across the blood-brain barrier. Neuropharmacology 1998; 37: 1553-1567.
34. Karege F, Schwald M, Cisse M: Postnatal developmental profile of brain-derived neuro-trophic factor in rat brain and platelets. Neu-rosci Lett 2002; 328: 261-264.
35. Schmidt HD, Duman RS: Peripheral BDNF produces antidepressant-like effects in cellular and behavioral models. Neuropsycho-pharmacology 2010; 35: 2378-2391.
36. Obrist PA: Cardiovascular Psychophysiolo-gy: A Perspective. London, Plenum, 1981, pp 18-23.
37. Kroenke K, Spitzer RL, Williams JB: The PHQ-9: validity of a brief depression severity measure. J Gen Intern Med 2001; 16: 606-613.
38. Monahan PO, Shacham E, Reece M, Kroen-ke K, Ong'or WO, Omollo O, et al: Validity/reliability of PHQ-9 and PHQ-2 depression scales among adults living with HIV/AIDS in western Kenya. J Gen Intern Med 2009; 24: 189-197.
39. Marfell-Jones M, Olds T, Stewart A, Carter JE: International Standards for Anthropo-metric Assessment. Potchefstroom, ISAK, 2006, p 137.
40. Klippel NJ, Heil DP: Validation of energy expenditure prediction algorithms in adults using the Actical electronic activity monitor. Med Sci Sports Exerc 2003; 35:S284.
41. Jarvis MJ, Feyerabend C, Bryant A, Hedges B, Primatesta P: Passive smoking in the home: plasma cotinine concentrations in non-smokers with smoking partners. Tob Control 2001; 10: 368-374.
42. Sharpe PC: Biochemical detection and monitoring of alcohol abuse and abstinence. Ann Clin Biochem 2001; 38: 652-664.
43. Tietze F: Enzymic method for quantitative determination of nanogram amounts of total and oxidized glutathione: applications to mammalian blood and other tissues. Ann Biochem 1969; 27: 502-522.
44. Grundy MS, Brewer H, Cleeman JI, Daniels SR, Donaato KA, Eckel RH, et al: Diagnosis and management of the metabolic syndrome. An American Heart Association/National Heart, Lung and Blood Institute scientific statement. Circulation 2005; 112: 2735-2752.
45. Prinsloo J, Malan L, de Ridder JH, Potgieter JC, Steyn HS: Determining the waist circumference cut off which best predicts the metabolic syndrome components in urban Africans: the SABPA study. Exp Clin Endocrinol Diabetes 2011; 119: 599-603.
46. Maes M, Ruckoanich P, Chang YS, Maha-nonda N, Berk M: Multiple aberrations in shared inflammatory and oxidative and ni-trosative stress pathways explain the co-as-sociation of depression and cardiovascular disorder (CVD), and the increased risk for CVD and due mortality in depressed patients. Prog Neuropsychopharmacol Biol Psychiatry 2011; 35: 769-783.
47. Griffith OW: Biologic and pharmacologic regulation of mammalian glutathione synthesis. Free Radic Biol Med 1999; 27: 922-935.
48. Bouligand J, Deroussent A, Paci A, Morizet J, Vassal G: Liquid chromatography-tandem mass spectrometry assay of reduced and oxidized glutathione and main precursors in mice liver. J Chromatogr B 2006; 832: 67-74.
49. Wong ML, Dong C, Andreev V, Arcos-Bur-gos M, Licinio J: Prediction of susceptibility to major depression by a model of interactions of multiple functional genetic variants and environmental factors. Mol Psychiatry 2012; 17: 624-633.
50. Bus BA, Molendijk ML, Penninx BJ, Buitelaar JK, Kenis G, Prickaerts J, Elzinga BM, Voshaar RC: Determinants of serum brain-derived neurotrophic factor. Psychoneuro-endocrinology 2011; 36: 228-239.
51. Grant MM, Barber VS, Griffiths HR: The presence of ascorbate induces expression of brain-derived neurotrophic factor in SH-SY5Y neuroblastoma cells after peroxide insult, which is associated with increased survival. Proteomics 2005; 5: 534-540.
52. He T, Katusic ZS: Brain-derived neurotroph-ic factor increases expression of MnSOD in human circulating angiogenic cells. Micro-vasc Res 2012; 83: 366-371
53. Duan W, Guo Z, Jiang H, Ware M, Mattson MP: Reversal of behavioral and metabolic abnormalities, and insulin resistance syndrome, by dietary restriction in mice deficient in brain-derived neurotrophic factor. Endocrinology 2003; 144: 2446-2453.
54. Numakawa T, Matsumoto T, Numakawa Y, Richards M, Yamawaki S, Kunugi H: Protective action of neurotrophic factors and estrogen against oxidative stress-mediated neuro-degeneration. J Toxicol 2011; 2011: 405194.
55. Castrén E, Võikar V, Rantamäki T: Role of neurotrophic factors in depression. Curr Opin Pharmacol 2007; 7: 18-21.
56. Maya Vetencourt JF, Sale A, Viegi A, Baroncelli L, De Pasquale R, O'Leary OF, et al: The antidepressant fluoxetine restores plasticity in the adult visual cortex. Science 2008; 320: 385-388.
57. Chollet F, Tardy J, Albucher JF, Thalamas C, Berard E, Lamy C, et al: Fluoxetine for mo-tor recovery after acute ischaemic stroke (FLAME): a randomised placebo-controlled trial. Lancet Neurol 2011; 10: 123-130.
58. Castrén E: Is mood chemistry? Nat Rev Neu-rosci 2005; 6: 241-246.
59. Meyer M, Matsuoka I, Wetmore C, Olson L, Thoenen H: Enhanced synthesis of brain-derived neurotrophic factor in the lesioned peripheral nerve: different mechanisms are responsible for the regulation of BDNF and NGF mRNA. J Cell Biol 1992; 119: 45-54.